Fibrinolytic Agents

Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.
DrugDrug NameDrug Description
DB00009AlteplaseA recombinant form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
DB00015ReteplaseA purified form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
DB00029AnistreplaseA form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.
DB00031TenecteplaseA modified form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.
DB00055Drotrecogin alfaA form of recombinant activated human protein C used to reduce mortality in patients with severe sepsis by inhibiting coagulation Factors V and VIII.
DB04932DefibrotideA mixture of single-stranded oligonucleotides used in the treatment of severe hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation.
DB05099AncrodAn anticoagulant purified from the venom of the Malayan pit viper that functions by inactivating circulating plasma fibrinogen. Not currently approved for use or marketed in any country.
DB06271SulodexideSulodexide has been used clinically for the prophylaxis and treatment of vascular diseases with increased risk of thrombosis, including intermittent claudication, peripheral arterial occlusive disease and post-myocardial infarc-tion. Also investigated...
DB06754DanaparoidA heparinoid with anticoagulant and antithrombotic activities used for the treatment of acute episode of Heparin-Induced Thrombocytopenia (HIT), and for prophylaxis in patients with a history of HIT.
DB06779DalteparinA low molecular weight heparin used for the prophylaxis of thrombotic events in certain patients and prevent acute cardiac ischemic events in patients with unstable angina and non-Q-wave myocardial infarction.
DB06822TinzaparinA low molecular weight heparin used for the treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with warfarin.
DB11312Protein CA medication used to treat protein C deficiency leading to purpura fulminans or coumarin-induced skin necrosis.
DB13199BrinaseNot Annotated
DB13646SaruplaseNot Annotated
DB00086StreptokinaseA purified fibrinolytic bacterial protein used to breakdown thrombosis in myocardial infarction, pulmonary embolism, and venous thromboembolism.
DB00261AnagrelideA platelet-reducing agent used in myeloproliferative disorders to prevent thrombotic complications.
DB04925DesmoteplaseInvestigated for use/treatment in cerebral ischemia and strokes.
DB05254FibrinolysinFibrinolysin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas.
DB06543AstaxanthinInvestigated for use/treatment in eye disorders/infections, cancer/tumors (unspecified), and asthma.
DB00013UrokinaseA low molecular weight form of human urokinase used to treat pulmonary embolism and myocardial infarction as well as to clear IV lines.
DB00054AbciximabA monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention.
DB00266DicoumarolFor decreasing blood clotting. Often used along with heparin for treatment of deep vein thrombosis.
DB00278ArgatrobanA synthetic direct thrombin inhibitor used for the prevention and treatment of thrombosis related to heparin use.
DB01088IloprostA synthetic prostacyclin analog indicated to treat pulmonary arterial hypertension (PAH).
DB06679AmediplaseInvestigated for use/treatment in myocardial infarction and thrombosis.
DB00569FondaparinuxAn anticoagulant used to prevent venous thromboembolism, to treat deep vein thrombosis, and to improve survival following myocardial infarction.
DB09075EdoxabanA novel oral anticoagulant used for reducing the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF).
DB12726MonteplaseMonteplase has been used in trials studying the treatment of Pulmonary Embolism.
DB15536Ferric chlorideNot Annotated
DrugDrug NameTargetType
DB00009AlteplaseUrokinase plasminogen activator surface receptortarget
DB00009AlteplaseFibrinogen alpha chaintarget
DB00009AlteplasePlasminogentarget
DB00009AlteplasePlasminogen activator inhibitor 1target
DB00015ReteplaseUrokinase plasminogen activator surface receptortarget
DB00015ReteplaseFibrinogen alpha chaintarget
DB00015ReteplasePlasminogentarget
DB00015ReteplasePlasminogen activator inhibitor 1target
DB00029AnistreplaseUrokinase plasminogen activator surface receptortarget
DB00029AnistreplaseFibrinogen alpha chaintarget
DB00029AnistreplasePlasminogentarget
DB00029AnistreplasePlasminogen activator inhibitor 1target
DB00031TenecteplaseUrokinase plasminogen activator surface receptortarget
DB00031TenecteplasePlasminogen activator inhibitor 1target
DB00031TenecteplaseFibrinogen alpha chaintarget
DB00031TenecteplasePlasminogen activator inhibitor 2target
DB00031TenecteplaseTetranectintarget
DB00031TenecteplaseKeratin, type II cytoskeletal 8target
DB00031TenecteplaseAnnexin A2target
DB00031TenecteplaseCalreticulintarget
DB00031TenecteplaseCalnexintarget
DB00031TenecteplaseProlow-density lipoprotein receptor-related protein 1target
DB00031TenecteplasePlasminogentarget
DB00055Drotrecogin alfaCoagulation factor VIIItarget
DB00055Drotrecogin alfaCoagulation factor Vtarget
DB00055Drotrecogin alfaPlasminogen activator inhibitor 1target
DB00055Drotrecogin alfaThrombomodulintarget
DB00055Drotrecogin alfaVitamin K-dependent protein Starget
DB00055Drotrecogin alfaCeruloplasmintarget
DB00055Drotrecogin alfaProthrombintarget
DB00055Drotrecogin alfaPlatelet factor 4target
DB00055Drotrecogin alfaPlasma serine protease inhibitortarget
DB00055Drotrecogin alfaSerpin B6target
DB00055Drotrecogin alfaVitamin K-dependent gamma-carboxylasetarget
DB00055Drotrecogin alfaEndothelial protein C receptortarget
DB04932DefibrotideAdenosine receptor A1target
DB04932DefibrotideAdenosine receptor A2atarget
DB04932DefibrotideAdenosine receptor A2btarget
DB05099AncrodFibrinogen alpha chaintarget
DB06271SulodexideHeparin cofactor 2target
DB06271SulodexideAntithrombin-IIItarget
DB06754DanaparoidAntithrombin-IIItarget
DB06779DalteparinVascular endothelial growth factor Atarget
DB06779DalteparinTissue factor pathway inhibitortarget
DB06779DalteparinHeparanaseenzyme
DB06779DalteparinAntithrombin-IIItarget
DB06779DalteparinP-selectintarget
DB06822TinzaparinAntithrombin-IIItarget
DB06822TinzaparinA disintegrin and metalloproteinase with thrombospondin motifs 4enzyme
DB06822TinzaparinIntegrin alpha-4target
DB06822TinzaparinStromal cell-derived factor 1target
DB00086StreptokinasePlasminogentarget
DB00086StreptokinaseProteinase-activated receptor 1target
DB00086StreptokinaseCytosolic phospholipase A2enzyme
DB00261AnagrelidecGMP-inhibited 3',5'-cyclic phosphodiesterase Atarget
DB00261AnagrelideCytochrome P450 1A2enzyme
DB04925DesmoteplasePlasminogentarget
DB05254FibrinolysinPlasminogen activator inhibitor 1target
DB05254FibrinolysinUrokinase-type plasminogen activatortarget
DB06543AstaxanthinNF-kappa-B inhibitor alphatarget
DB00013UrokinaseUrokinase plasminogen activator surface receptortarget
DB00013UrokinasePlasminogentarget
DB00013UrokinaseUrokinase-type plasminogen activatortarget
DB00013UrokinaseTissue-type plasminogen activatortarget
DB00013UrokinasePlasminogen activator inhibitor 2target
DB00013UrokinasePlasminogen activator inhibitor 1target
DB00013UrokinasePlasma serine protease inhibitortarget
DB00013UrokinaseNidogen-1target
DB00013UrokinaseLow-density lipoprotein receptor-related protein 2target
DB00013UrokinaseSuppressor of tumorigenicity 14 proteintarget
DB00054AbciximabIntegrin beta-3target
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00054AbciximabComplement C1r subcomponenttarget
DB00054AbciximabComplement C1q subcomponent subunit Atarget
DB00054AbciximabComplement C1q subcomponent subunit Btarget
DB00054AbciximabComplement C1q subcomponent subunit Ctarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00054AbciximabComplement C1s subcomponenttarget
DB00054AbciximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00054AbciximabIntegrin alpha-IIbtarget
DB00054AbciximabVitronectintarget
DB00266DicoumarolVitamin K epoxide reductase complex subunit 1target
DB00266DicoumarolNAD(P)H dehydrogenase [quinone] 1target
DB00266DicoumarolQuinone oxidoreductasetarget
DB00266DicoumarolCytochrome P450 2C9enzyme
DB00266DicoumarolSerum albumincarrier
DB00266DicoumarolCytochrome P450 2C6enzyme
DB00266DicoumarolCytochrome P450 2C11enzyme
DB00278ArgatrobanProthrombintarget
DB00278ArgatrobanCytochrome P450 3A4enzyme
DB00278ArgatrobanCytochrome P450 3A5enzyme
DB00278ArgatrobanSerum albumincarrier
DB00278Argatrobanalpha1-acid glycoproteincarrier
DB01088IloprostProstacyclin receptortarget
DB01088IloprostTissue-type plasminogen activatortarget
DB01088IloprostcAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB01088IloprostSolute carrier organic anion transporter family member 2B1transporter
DB01088IloprostSolute carrier organic anion transporter family member 2A1transporter
DB01088IloprostSolute carrier organic anion transporter family member 3A1transporter
DB01088IloprostcAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB01088IloprostcAMP-specific 3',5'-cyclic phosphodiesterase 4Ctarget
DB01088IloprostcAMP-specific 3',5'-cyclic phosphodiesterase 4Dtarget
DB01088IloprostProstaglandin E2 receptor EP1 subtypetarget
DB01088IloprostProstaglandin D2 receptor 2target
DB00569FondaparinuxAntithrombin-IIItarget
DB00569FondaparinuxCoagulation factor Xtarget
DB09075EdoxabanCoagulation factor Xtarget
DB09075EdoxabanP-glycoprotein 1transporter